Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US02043Q1076
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.14 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 40.24 | |||||
Debt-to-EBITDA | -15.19 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.06 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 50.6 | |||||
3-Year EBITDA Growth Rate | 34.2 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 23.78 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.19 | |||||
9-Day RSI | 40.83 | |||||
14-Day RSI | 40.9 | |||||
6-1 Month Momentum % | 47.79 | |||||
12-1 Month Momentum % | 28.2 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.75 | |||||
Quick Ratio | 2.69 | |||||
Cash Ratio | 2.28 | |||||
Days Inventory | 104.56 | |||||
Days Sales Outstanding | 57.08 | |||||
Days Payable | 83.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.37 | |||||
Operating Margin % | -8.98 | |||||
Net Margin % | -15.86 | |||||
FCF Margin % | 0.77 | |||||
ROA % | -8.43 | |||||
ROIC % | -18.55 | |||||
ROC (Joel Greenblatt) % | -26.01 | |||||
ROCE % | -6.41 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 14.66 | |||||
PB Ratio | 965.18 | |||||
Price-to-Tangible-Book | 969.04 | |||||
Price-to-Free-Cash-Flow | 2106.61 | |||||
Price-to-Operating-Cash-Flow | 554.37 | |||||
EV-to-EBIT | -161.53 | |||||
EV-to-Forward-EBIT | -993.33 | |||||
EV-to-EBITDA | -352.27 | |||||
EV-to-Forward-EBITDA | 258.86 | |||||
EV-to-Revenue | 14.41 | |||||
EV-to-Forward-Revenue | 11.35 | |||||
EV-to-FCF | 1879.25 | |||||
Price-to-Median-PS-Value | 0.2 | |||||
Earnings Yield (Greenblatt) % | -0.62 | |||||
FCF Yield % | 0.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALNY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Alnylam Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,094.795 | ||
EPS (TTM) ($) | -2.62 | ||
Beta | 0.33 | ||
Volatility % | 69.41 | ||
14-Day RSI | 40.9 | ||
14-Day ATR ($) | 8.166103 | ||
20-Day SMA ($) | 249.4275 | ||
12-1 Month Momentum % | 28.2 | ||
52-Week Range ($) | 141.975 - 304.39 | ||
Shares Outstanding (Mil) | 128.98 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alnylam Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Alnylam Pharmaceuticals Inc Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc(ALNY)'s stock price today?
When is next earnings date of Alnylam Pharmaceuticals Inc(ALNY)?
Does Alnylam Pharmaceuticals Inc(ALNY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |